Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial to Assess the Efficacy and Safety of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT03697603 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial to Assess the Efficacy and Safety of Brexpiprazole as Adjunctive Therapy in Patients With Major Depressive Disorder
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- July 30, 2018
- Completion date
- July 4, 2022
- Enrollment
- 740 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.